is ozempic a glp-1 receptor agonists Weight-loss drugs such as were in the headlines lot in 2025 – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ The Societal Impact of GLP-1

Obesity is associated with increased basal and postprandial -cell insulin secretion even in the absence of insulin resistance

Effective integration requires multidisciplinary teams including pediatric endocrinologists, registered dietitians, mental health professionals, and exercise physiologists

PART 1: GLP 1 Agonist-based Therapies: How do they work

Moreover, tirzepatide leads to a reduction in liver fat, macroalbuminuria, blood pressure, and lipids [13]

Before you make your next trade, you'll want to hear this

Retatrutide (Eli Lilly), a triagonist currently in phase III clinical trials (TRIUMPH-1 NCT05929066 and others 3 ) adds a glucagon receptor agonist to its mechanism of action, promising an even greater impact on weight loss